Literature DB >> 12228121

FDA advisers warn of more deaths if drug is relaunched.

Ray Moynihan.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12228121      PMCID： PMC1124095          DOI： 10.1136/bmj.325.7364.561

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  Alosetron: a case study in regulatory capture, or a victory for patients' rights?

Authors:  Ray Moynihan
Journal:  BMJ       Date:  2002-09-14

Review 2.  Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

Authors:  Anthony Lembo; H Christian Weber; Francis A Farraye
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?

Authors:  Viola Andresen; Stephan Hollerbach
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Functional Somatic Syndromes: Emerging Biomedical Models and Traditional Chinese Medicine.

Authors:  Steven Tan; Kirsten Tillisch; Emeran Mayer
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.